Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.54 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.50 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515604 | 0.88 | MAPT (0.69) | MAPTPKMPOLBHCAR3LMNA | |
| SCHEMBL18116062 | 0.86 | MAPT (0.59) | MAPTPKMPOLBHCAR3LMNA | |
| SCHEMBL197978 | 0.83 | PKM (0.67) | MAPTPKMPOLBLMNASMN1; SMN2 | |
| SCHEMBL29516580 | 0.83 | PKM (0.67) | MAPTPKMPOLBLMNASMN1; SMN2 | |
| SCHEMBL12760575 | 0.83 | MAPT (0.62) | MAPTPKMPOLBHCAR3LMNA | |
| SCHEMBL16151564 | 0.82 | KAT2B (0.72) | MAPTPKMPOLBHCAR3LMNA | |
| SCHEMBL20968369 | 0.82 | HCAR3 (0.66) | MAPTPKMPOLBHCAR3LMNA | |
| SCHEMBL16152114 | 0.82 | HCAR3 (0.66) | MAPTPKMPOLBHCAR3LMNA | |
| SCHEMBL10428098 | 0.82 | HCAR3 (0.66) | MAPTPKMPOLBHCAR3LMNA | |
| SCHEMBL10895100 | 0.82 | HCAR3 (0.70) | MAPTPKMPOLBHCAR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185176-A1 | Heparanase inhibitors and uses thereof | INSIGHT BIOHARMACEUTICALS LTD. (IL) | 2007-08-09 | — | — | US | disclosed |
| EP-1720828-A2 | HEPARANASE INHIBITORS AND USES THEREOF | Insight Biopharmaceuticals Ltd (IL) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005074375-A2 | HEPARANASE INHIBITORS AND USES THEREOF | INSIGHT BIOPHARMACEUTICALS LTD (IL) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185176-A1 | Heparanase inhibitors and uses thereof | HPSE, ENGASE, HEXA | MAPT 4234/4885PKM 3794/4885POLB 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.